Interviews
CEO, Tim McCarthy joins Stockhouse – “Putting Patients into Remission”: ImmuPharma’s Autoimmune Breakthrough with P140
Zak Mir talks to Tim McCarthy, CEO Immupharma, in the wake of the specialty biopharmaceutical company that discovers and develops peptide-based therapeutics, announcing the filing of a groundbreaking new patent application for its lead asset P140, the world’s first “Immunormalizer.”
Tim McCarthy, CEO, and Dr Sébastien Goudreau, CSO, joins Sunday Roast Podcast to discuss a groundbreaking patent for its lead asset P140, the world’s first “Immunormalizer,” – September 2025
ImmuPharma’s CEO Tim McCarthy and CSO Dr Sébastien Goudreau talk with Proactive Investor about the Company’s latest milestone — the filing of a new patent application for its lead autoimmune drug therapy, P140, described as the world’s first “immunormaliser’ – September 2025
Tim McCarthy, CEO of ImmuPharma talks to Zak MIr at ‘Traders Cafe’ focusing on the UK biotech arena as a public company together with two key significant scientific announcements issued by ImmuPharma over the last period, including more details on the MOA of IMMs auto-immune technology platform, P140 – March 2025
ImmuPharma’s CEO, Tim McCarthy talks again to Sunday Roast investment podcast, to give detail on the recent announcement on the mechanism of action of IMMs autoimmune P140 technology and how important this is in current and future business development discussions – March 2025
Tim McCarthy, CEO of ImmuPharma talks to Proactive Investor about the recent oversubscribed fundraising and strong outlook for 2025 – February 2025
Tim McCarthy, CEO of ImmuPharma, joins Sunday Roast podcast to discuss how the company is revolutionizing healthcare with peptide-based therapies – Jan 2025
ImmuPharma’s CEO Tim McCarthy shares latest developments with P140 platform and exciting road ahead with business development over 2025 – January 2025
ImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developments – 6 March 2024
Zak Mir talks to Tim McCarthy, Chairman and CEO, Immupharma, about the recent fund raise, highlights of the company’s portfolio, and the main focus of its drug discovery and development strategy – 22 September 2023
ImmuPharma “absolutely delighted” to push on with new clinical trial – 28 June 2023
Tim McCarthy, CEO of ImmuPharma talks to Proactive Investors on the recent positive guidance from the FDA on its autoimmune program, CIDP – 24 May 2023
Tim McCarthy, CEO talks to Proactive on recent positive newsflow and his optimism on the forthcoming FDA meetings for Lupuzor for lupus and CIDP – 27 April 2023
Tim McCarthy, CEO of ImmuPharma talks to Proactive Investor on recent news which confirms that Lupuzor will move into a Phase 2/3 adaptive study in H2 2023 – February 2023